An independent digest that writes specifications, not scores

What this site is

Peptide Precision Planner is an independent literature digest covering four research peptides: BPC-157, MOTS-c, tirzepatide and CJC-1295. It sells nothing, arranges nothing and has no clinical practice attached to it.

It exists because the ordinary way of writing about these compounds produces a predictable distortion. Summarise the findings and a compound with a hundred rodent papers reads as better established than a compound with one well-run human trial. Volume substitutes for maturity, and mechanism substitutes for outcome.

The fix used here is to organise everything around study design rather than around results. Which question was asked, which design can answer that class of question, and which of these four has that design. The finished product of an entry is not a verdict but a brief: the specification of the study the field has not yet run.

How a design brief gets written

Every compound page closes with one, and they follow the same five headings so they can be compared: population, comparator, endpoint, duration and size. Two further fields appear when the record demands them — a prerequisite study that must come first, and a constraint inherited from the existing literature.

Nothing in a brief is invented. Each field is derived from something already in the record. The prerequisite in the BPC-157 brief follows from the published pharmacokinetics ^[3]. The exercise-matched control arm in the MOTS-c brief follows from the finding that exercise itself raises the endogenous peptide ^[9]. The insistence on naming the variant in the CJC-1295 brief follows from the measured half-life of the long-acting form ^[21]. The rare-event requirement in the tirzepatide brief follows from a signal that only became visible when nine trials were pooled ^[15].

A brief written this way is falsifiable in a modest but real sense: if the study is ever run, the specification either anticipated its design or it did not.

What counts as an answer here

Three rules govern the prose.

A quantity is reported with the source that measured it, or it is not reported. Percentages, participant counts, durations, effect sizes and half-lives all carry a bracketed reference to the numbered list on the sources page.

An absence is stated as an absence. Where no study exists, the page says no study exists rather than reaching for the nearest adjacent finding. Three of the six sections on a compound page can be written from the literature with confidence; the fourth sometimes has to report that the literature is silent, and that sentence is not a failure of the page.

Community reports are kept, labelled and quarantined. They appear because the distance between what people report and what has been measured is the subject of this site, and they are marked as anecdotal, not clinical evidence, wherever they appear. They are never given quantities and are never allowed to stand in for a finding.

What this planner will not publish

The name promises planning, and the planning is real, but its object is a study. Stating the boundary once more, because it governs every page: no quantities, no intervals, no combinations and no sequences intended for a person appear anywhere on this site.

Where a number from a published experiment appears — the amounts given to volunteers in the CJC-1295 pharmacology studies, for instance ^[21][22] — it is presented as a description of that experiment. It is not scaled, not converted, and not carried into a recommendation. The arithmetic that would do so is not performed here.

This is not defensive drafting. Three of these four compounds have no approved human indication, which means there is no dosing standard anywhere in the world to report accurately. Any figure that read as guidance would have originated on this page rather than in the literature, and inventing one would contradict the only thing this site is for.